2,019 research outputs found

    The decay Bs -> mu+ mu-: updated SUSY constraints and prospects

    Get PDF
    We perform a study of the impact of the recently released limits on BR(Bs -> mu+ mu-) by LHCb and CMS on several SUSY models. We show that the obtained constraints can be superior to those which are derived from direct searches for SUSY particles in some scenarios, and the use of a double ratio of purely leptonic decays involving Bs -> mu+ mu- can further strengthen such constraints. We also discuss the experimental sensitivity and prospects for observation of Bs -> mu+ mu- during the sqrt(s)=7 TeV run of the LHC, and its potential implications.Comment: 30 pages, 21 figures. v2: Improved discussion of constraints from B -> tau nu, references adde

    Effects of accelerated versus standard care surgery on the risk of acute kidney injury in patients with a hip fracture : A substudy protocol of the hip fracture Accelerated surgical TreaTment and Care tracK (HIP ATTACK) international randomised controlled trial

    Get PDF
    Introduction Inflammation, dehydration, hypotension and bleeding may all contribute to the development of acute kidney injury (AKI). Accelerated surgery after a hip fracture can decrease the exposure time to such contributors and may reduce the risk of AKI. Methods and analysis Hip fracture Accelerated surgical TreaTment And Care tracK (HIP ATTACK) is a multicentre, international, parallel-group randomised controlled trial (RCT). Patients who suffer a hip fracture are randomly allocated to either accelerated medical assessment and surgical repair with a goal of surgery within 6 hours of diagnosis or standard care where a repair typically occurs 24 to 48 hours after diagnosis. The primary outcome of this substudy is the development of AKI within 7 days of randomisation. We anticipate at least 1998 patients will participate in this substudy. Ethics and dissemination We obtained ethics approval for additional serum creatinine recordings in consecutive patients enrolled at 70 participating centres. All patients provide consent before randomisation. We anticipate reporting substudy results by 2021. Trial registration number NCT02027896; Pre-results
    corecore